◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY
Home › All stocks › IMVT › Operating Income

Immunovant, Inc. (IMVT) Operating Income 2022–2026

DATA UPDATED 2026-07-09

Immunovant, Inc. annual operating income for fiscal 2026 was -$533 million, a decrease of 21.6% from -$438 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

IMVT Annual Operating Income

Operating Income (annual)2026-03-312025-03-312024-03-312023-03-312022-03-31
Operating Income (EBIT)($533M)($438M)($270M)($208M)—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IMVT Quarterly Operating Income

Operating Income (quarterly)2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Income (EBIT)($160M)($114M)($132M)($127M)($114M)—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More IMVT metrics: Revenue · Net Income · EPS · Free Cash Flow

All IMVT financial statements → Interactive IMVT charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.